Chemistry Reference
In-Depth Information
OP
organophosphate
p.o.
Per os
q.i.d.
quarter in die ( ¼ four times a day)
r.t.
room temperature
SAR
structure activity relationship
s.c.
subcutaneously
SMD
steered molecular dynamics
t.i.d.
ter in die ( ¼ three times a day)
TCM
traditional Chinese medicine
TcAChE
Torpedo californica AChE
REFERENCES
1. Liu, J. S.; Zhu, Y. L.; Yu, C. M.; Zhou, Y. Z.; Han, Y. Y.; Wu, F. W.; Qi, B. F. The
structures of huperzines A and B, two new alkaloids exhibiting marked anticholinester-
ase activity. Can. J. Chem., 1986, 64: 837-839.
2. Xu, Z. L.; Chu, B. M.; Luan, X. H.; Wu, W. Z.; Cai, D. G. Structural identification of
Fordine. Med. J. Chinese PLA (in Chinese), 1985, 10(4): 263-264.
3. Wang, Y. E.; Yue, D. X.; Tang, X. C. Anticholinesterase activity of huperzine A. Acta
Pharmacol. Sin., 1986, 7(2): 110-113.
4. Tang, X. C.; He, X. C.; Bai, D. L. Huperzine A: a novel acetylcholinesterase inhibitor.
Drugs Future, 1999, 24(6): 647-663.
5. Tang, X. C.; Han, Y. F. Pharmacological profile of huperzine A, a novel acetylcholi-
nesterase inhibitor from Chinese herb. CNS Drug Rev., 1999, 5(3): 281-300.
6. Kozikowski, A. P.; Tuckmantel W. Chemistry, pharmacology, and clinical efficacy of
chinese nootropic agent huperzine A. Acc. Chem. Res., 1999, 32: 641-650.
7. Bai, D. L.; Tang, X. C.; He, X. C. Huperzine A, potential therapeutic agent for treatment
of Alzheimer's disease. Curr. Med. Chem., 2000, 7: 355-374.
8. Zeng, F. X.; Jiang, H. L.; Yang, Y. S.; Chen, K. X.; Ji, R. Y. Progress in synthesis and
structural modification of huperzine A. Prog. Chem., 2000, 12(1): 63-76.
9. Zangara, A. The psychopharmacology of huperzine A: an alkaloid with cognitive
enhancing and neuroprotective properties of interest in the treatment of Alzheimer's
disease. Pharmarcol. Biochem. Behav., 2003, 75(3): 675-686.
10. Jiang, H. L.; Bai, D. L.; Luo, X. M. Progress in clinic, pharmacological, chemical
and structural biological studies of huperzine A: a drug of traditional Chinese
medicine origin for the treatment of Alzheimer's disease. Curr. Med. Chem., 2003,
10: 2231-2252.
11. Ghiso, J.; Frangione, B. Amyloidosis and Alzheimer's disease. Adv. Drug Deliver Rev.,
2002, 54: 1539-1551.
12. Farlow, M.; Gracon, S. I.; Hershey, L. A.; Lewis, K. W.; Sadowsky, C. H.; DolanUreno, J.
A controlled trial of tacrine in Alzheimer's disease. JAMA, 1992, 268: 2523-2529.
13. Knapp, M. J.; Knopman, D. S.; Solomon, P. R.; Pendlebury, W. W.; Davis, C. S.; Gracon,
S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with
Alzheimer's disease. JAMA, 1994, 271: 985-991.
 
Search WWH ::




Custom Search